MSB 1.86% $1.32 mesoblast limited

Cell Therapy News/Articles, page-16746

  1. 17,161 Posts.
    lightbulb Created with Sketch. 2422
    "The size of this trial is relatively small. And again, until we have full agreement with the agency, we need to be a little bit circumspect. But we are looking at per arm something like 60 to 70 patients, something like that per arm. And the overall cost, given that we are working with the CTN, it's going to be in the mid single-digits, that sort of thing.

    So, we are talking about relatively inexpensive trial costs. And so when you say, how much will this offset around 25% cost reduction, over the next six months, a very little will offset good reduction"

    So why not do this trial years ago instead of spending years and several hundred million dollars of investor funds trying to get the FDA to approve Remestemcel for children with a hopelessly inadequate trial? It beggars belief, unless SI is afraid the results won't show significant efficacy.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.32
Change
-0.025(1.86%)
Mkt cap ! $1.507B
Open High Low Value Volume
$1.35 $1.35 $1.31 $2.699M 2.040M

Buyers (Bids)

No. Vol. Price($)
2 34995 $1.32
 

Sellers (Offers)

Price($) Vol. No.
$1.33 10374 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.